Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David S Rubenstein

Showing results (51-60 of 52) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 52 results.
Journal of the American Academy of Dermatology|May 22, 2024
Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trialsJonathan I Silverberg, Lawrence F Eichenfield, Adelaide A Hebert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2015
IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in MelanomaCraig C Carson, Stergios J Moschos, Sharon N Edmiston, et al.
Pageof 6

Showing results (51-60 of 52) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 52 results.
Journal of the American Academy of Dermatology|May 22, 2024
Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trialsJonathan I Silverberg, Lawrence F Eichenfield, Adelaide A Hebert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2015
IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in MelanomaCraig C Carson, Stergios J Moschos, Sharon N Edmiston, et al.
Pageof 6